Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: DPP4

Gene summary for DPP4

Gene summary.

Gene information	Species	Human
	Gene symbol	DPP4
	Gene ID	1803
	Gene name	dipeptidyl peptidase 4
	Gene Alias	ADABP
	Cytomap	2q24.2
	Gene Type	protein-coding
	GO ID	GO:0001662
	UniProtAcc	P27487

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
1803	DPP4	HCC1_Meng	Human	Liver	HCC	4.66e-44	1.19e-01	0.0246
1803	DPP4	HCC1	Human	Liver	HCC	3.99e-30	4.76e+00	0.5336
1803	DPP4	HCC2	Human	Liver	HCC	4.92e-27	4.42e+00	0.5341
1803	DPP4	Pt13.b	Human	Liver	HCC	7.74e-06	9.34e-02	0.0251
1803	DPP4	S014	Human	Liver	HCC	1.39e-38	1.44e+00	0.2254
1803	DPP4	S015	Human	Liver	HCC	8.55e-30	1.78e+00	0.2375
1803	DPP4	S016	Human	Liver	HCC	4.88e-41	1.61e+00	0.2243
1803	DPP4	S027	Human	Liver	HCC	4.46e-07	6.62e-01	0.2446
1803	DPP4	S028	Human	Liver	HCC	1.17e-32	1.04e+00	0.2503
1803	DPP4	S029	Human	Liver	HCC	7.41e-32	1.09e+00	0.2581
1803	DPP4	RNA-P25T1-P25T1-1	Human	Lung	AIS	1.17e-16	8.63e-01	-0.2116
1803	DPP4	RNA-P25T1-P25T1-2	Human	Lung	AIS	1.90e-06	9.17e-01	-0.1941
1803	DPP4	RNA-P25T1-P25T1-3	Human	Lung	AIS	3.89e-08	7.98e-01	-0.2107
1803	DPP4	RNA-P25T1-P25T1-4	Human	Lung	AIS	1.32e-15	7.99e-01	-0.2119
1803	DPP4	RNA-P6T2-P6T2-1	Human	Lung	IAC	2.11e-16	6.18e-01	-0.0166
1803	DPP4	RNA-P6T2-P6T2-2	Human	Lung	IAC	1.69e-22	6.59e-01	-0.0132
1803	DPP4	RNA-P6T2-P6T2-3	Human	Lung	IAC	2.63e-26	6.02e-01	-0.013
1803	DPP4	RNA-P6T2-P6T2-4	Human	Lung	IAC	2.24e-18	6.05e-01	-0.0121
1803	DPP4	RNA-P7T1-P7T1-2	Human	Lung	AIS	5.45e-06	5.70e-01	-0.0876
1803	DPP4	RNA-P7T1-P7T1-3	Human	Lung	AIS	9.39e-03	4.76e-01	-0.0822

Page: 1 2 3

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001603222	Liver	HCC	viral process	286/7958	415/18723	4.41e-28	1.86e-25	286
GO:002241112	Liver	HCC	cellular component disassembly	282/7958	443/18723	1.02e-19	1.38e-17	282
GO:001905822	Liver	HCC	viral life cycle	209/7958	317/18723	2.05e-17	2.09e-15	209
GO:004440322	Liver	HCC	biological process involved in symbiotic interaction	183/7958	290/18723	9.13e-13	4.59e-11	183
GO:005170122	Liver	HCC	biological process involved in interaction with host	128/7958	203/18723	2.51e-09	6.91e-08	128
GO:005212612	Liver	HCC	movement in host environment	109/7958	175/18723	9.58e-08	1.89e-06	109
GO:000166612	Liver	HCC	response to hypoxia	172/7958	307/18723	1.06e-06	1.59e-05	172
GO:003629312	Liver	HCC	response to decreased oxygen levels	179/7958	322/18723	1.29e-06	1.87e-05	179
GO:007048212	Liver	HCC	response to oxygen levels	191/7958	347/18723	1.42e-06	2.03e-05	191
GO:004440912	Liver	HCC	entry into host	88/7958	151/18723	6.47e-05	5.91e-04	88
GO:004671812	Liver	HCC	viral entry into host cell	83/7958	144/18723	1.73e-04	1.36e-03	83
GO:004578512	Liver	HCC	positive regulation of cell adhesion	215/7958	437/18723	2.53e-03	1.22e-02	215
GO:003559212	Liver	HCC	establishment of protein localization to extracellular region	176/7958	360/18723	7.96e-03	3.15e-02	176
GO:000930612	Liver	HCC	protein secretion	175/7958	359/18723	9.32e-03	3.57e-02	175
GO:000166721	Liver	HCC	ameboidal-type cell migration	226/7958	475/18723	1.35e-02	4.81e-02	226
GO:00160328	Lung	IAC	viral process	94/2061	415/18723	5.11e-12	4.27e-09	94
GO:00190588	Lung	IAC	viral life cycle	77/2061	317/18723	1.23e-11	4.83e-09	77
GO:00521268	Lung	IAC	movement in host environment	48/2061	175/18723	1.30e-09	2.21e-07	48
GO:00517018	Lung	IAC	biological process involved in interaction with host	52/2061	203/18723	3.74e-09	5.84e-07	52
GO:00467188	Lung	IAC	viral entry into host cell	41/2061	144/18723	6.27e-09	9.08e-07	41

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

DPP4

SNV

Missense_Mutation

novel

c.1444N>A

p.Leu482Ile

p.L482I

P27487

protein_coding

deleterious(0.05)

benign(0.258)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DPP4

SNV

Missense_Mutation

rs755540270

c.1051N>G

p.Thr351Ala

p.T351A

P27487

protein_coding

deleterious(0.02)

benign(0.112)

TCGA-AR-A2LK-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

anastrozole

DPP4

SNV

Missense_Mutation

c.1394N>T

p.Ala465Val

p.A465V

P27487

protein_coding

deleterious(0.01)

possibly_damaging(0.675)

TCGA-B6-A0IB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

DPP4

SNV

Missense_Mutation

c.2222N>A

p.Gly741Glu

p.G741E

P27487

protein_coding

deleterious(0)

probably_damaging(0.953)

TCGA-B6-A0X1-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DPP4

SNV

Missense_Mutation

c.779N>C

p.Gly260Ala

p.G260A

P27487

protein_coding

deleterious(0.01)

probably_damaging(0.928)

TCGA-BH-A0DX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

DPP4

SNV

Missense_Mutation

novel

c.1493N>T

p.Ser498Leu

p.S498L

P27487

protein_coding

tolerated(0.13)

benign(0.007)

TCGA-BH-A2L8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

DPP4

SNV

Missense_Mutation

rs752793888

c.1067N>A

p.Arg356Lys

p.R356K

P27487

protein_coding

tolerated(0.52)

benign(0.084)

TCGA-C8-A26Y-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

DPP4

SNV

Missense_Mutation

c.67N>A

p.Val23Met

p.V23M

P27487

protein_coding

tolerated(0.16)

probably_damaging(0.988)

TCGA-D8-A1XM-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

DPP4

deletion

Frame_Shift_Del

rs779957190

c.135_138delAACT

p.Thr46IlefsTer3

p.T46Ifs*3

P27487

protein_coding

TCGA-A2-A3XW-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamyicin

DPP4

SNV

Missense_Mutation

c.2072N>C

p.Arg691Thr

p.R691T

P27487

protein_coding

deleterious(0)

probably_damaging(0.95)

TCGA-DG-A2KK-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME	inhibitor	CHEMBL2105762	OMARIGLIPTIN
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME		VILDAGLIPTIN	VILDAGLIPTIN
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME		Beta-phe compound 2
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME		Imidazo cyclohexylamine derivative 3
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME		Peptide analog 47
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME		ENALAPRIL	ENALAPRIL	16678199
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME		Dutogliptin	DUTOGLIPTIN
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME	inhibitor	CHEMBL3833357	BEGELOMAB
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME	inhibitor	363894186	TALABOSTAT
1803	DPP4	PROTEASE, CELL SURFACE, DRUGGABLE GENOME, ENZYME		PMID25482888-Compound-52

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13